4.5 Article

Early Management of Patients With Acute Heart Failure: State of the Art and Future Directions. A Consensus Document From the Society for Academic Emergency Medicine/Heart Failure Society of America Acute Heart Failure Working Group

Journal

JOURNAL OF CARDIAC FAILURE
Volume 21, Issue 1, Pages 27-43

Publisher

CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
DOI: 10.1016/j.cardfail.2014.07.003

Keywords

Acute heart failure; emergency medicine; early management

Funding

  1. National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) [K23HL085387]
  2. Medtronic
  3. Cardiorentis
  4. Abbott Point-of-Care
  5. Novartis
  6. Medicines Company
  7. Astellas
  8. Intersection Medical
  9. Radiometer
  10. Abbott Diagnostics
  11. Centers for Medicaid and Medicare Services (CMS)
  12. NIH/NHLBI [K12HL1090]
  13. National Center for Advancing Translational Sciences [UL1TR000445]
  14. Roche Diagnostics
  15. NIH [RO10HL105448, U-10HL110312]
  16. European Union
  17. Health Resources and Services Administration
  18. Amgen
  19. Trevena
  20. Portola
  21. Siemens
  22. Insys
  23. Mayday Fund Pfizer
  24. NHLBI
  25. Sanofi Aventis
  26. Dyax
  27. Novartis Pharmaceuticals
  28. Trevena, Inc.
  29. Mespere
  30. BG Medicine
  31. NIH/NIMHD [5 R01 MD005849-04]
  32. Abbott
  33. Alere
  34. Banyan
  35. Roche
  36. Acorda Therapeutics
  37. Cardio3 Bioscience
  38. Cytokinetics
  39. Sorbent Therapeutics
  40. St Jude

Ask authors/readers for more resources

Heart failure (HF) afflicts nearly 6 million Americans, resulting in one million emergency department (ED) visits and over one million annual hospital discharges. An aging population and improved survival from cardiovascular diseases is expected to further increase I-IF prevalence. Emergency providers play a significant role in the management of patients with acute heart failure (AHF). It is crucial that emergency physicians and other providers involved in early management understand the latest developments in diagnostic testing, therapeutics and alternatives to hospitalization. Further, clinical trials must be conducted in the ED in order to improve the evidence base and drive optimal initial therapy for ARE Should ongoing and future studies suggest early phenotype-driven therapy improves in-hospital and post-discharge outcomes, ED treatment decisions will need to evolve accordingly. The potential impact of future studies which incorporate risk-stratification into ED disposition decisions cannot be underestimated. Predictive instruments that identify a cohort of patients safe for ED discharge, while simultaneously addressing barriers to successful outpatient management, have the potential to significantly impact quality of life and resource expenditures.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available